The increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis are driving the growth of the Digital Breast Tomosynthesis (DBT) Market at a CAGR of 11.68% during the forecast period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Digital Breast Tomosynthesis (DBT) Market” that contains the information from 2019 to 2035.

The Global Digital Breast Tomosynthesis (DBT) Market is estimated to register a CAGR of 11.68 % during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Digital Breast Tomosynthesis (DBT) Market — Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. and others.

The Global Digital Breast Tomosynthesis (DBT) Market accounted for registering a CAGR of 11.68 % during the forecast period and is estimated to reach USD 13.18 billion by 2035.

The rising global prevalence of breast cancer is a key driver behind the rapid growth of the digital breast tomosynthesis (DBT) market. According to the WHO, in 2022 alone, 2.3 million women were diagnosed with breast cancer, and 670,000 died from the disease, underscoring the critical need for early and accurate detection. In the U.S., the National Breast Cancer Foundation, Inc. reports that 1 in 8 women will be diagnosed with breast cancer in their lifetime, with 316,950 women and 2,800 men expected to be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive (in situ) breast cancer. 

These alarming statistics have intensified demand for advanced screening technologies like 3D mammography (tomosynthesis), which offers higher detection rates and fewer false positives compared to traditional 2D mammography. Governments and healthcare providers are increasingly adopting DBT in screening programs, while technological advancements and growing awareness further propel market expansion. As a result, the global tomosynthesis market is experiencing robust growth, driven by the urgent need for improved breast cancer diagnostics and early intervention.

Segmental Analysis

The Global Digital Breast Tomosynthesis (DBT) Market has been segmented based on Product, by Configuration, by Application, by End-User.

Based on Product, this segment includes 2D/3D Combo and 3D-Only. The 2D/3D Combo segment dominated the global market in 2024, while the 3D-Only segment is projected to be the fastest–growing segment during the forecast period. The 2D/3D combination mammogram is an advanced method for breast cancer screening that uses both traditional 2D mammography and 3D tomosynthesis. The 2D mammogram captures a standard image of the breast from two angles, while the 3D tomosynthesis takes multiple images from different angles and puts them together to create a detailed 3D picture. This combination helps doctors find problems more accurately, especially in women with dense breast tissue where 2D images might miss some issues. The 2D/3D combo also reduces the chances of false positives, meaning fewer women will need unnecessary follow-up tests. While there’s a slight increase in radiation exposure compared to a regular 2D mammogram, the extra clarity and accuracy make it a valuable tool for early breast cancer detection.

Based on Configuration, this segment includes U-Arm and Others. The Others segment dominated the global market in 2024, while the U-Arm segment is projected to be the fastest–growing segment during the forecast period. C-arm tomosynthesis devices are emerging as a valuable innovation in the breast cancer diagnostics, offering high-resolution 3D imaging that significantly enhances the accuracy of tumor detection and characterization. Unlike conventional 2D mammography, tomosynthesis captures multiple images from different angles, allowing radiologists to examine breast tissue in thin slices and identify malignancies that may be obscured in dense tissue. These systems are particularly beneficial in biopsy guidance and intraoperative imaging, enabling precise localization and assessment of lesions. As healthcare providers seek to improve early detection rates and reduce recall rates, the demand for C-arm tomosynthesis solutions tailored to breast cancer applications is growing steadily, supported by advancements in imaging technology and increased focus on patient-centered care.

Based on Application, this segment includes Breast Cancer Screening and Diagnostic Imaging. The Breast Cancer Screening segment dominated the global market in 2024, while the Diagnostic Imaging segment is projected to be the fastest–growing segment during the forecast period. The use of tomosynthesis in breast cancer screening is revolutionizing community health methods by boosting early detection rates, particularly in women with thick breast tissue. As a screening modality, 3D tomosynthesis greatly reduces recall rates and false positives, hence improving clinical workflow and lowering downstream costs associated with unnecessary follow-up imaging. Healthcare providers who use tomosynthesis for routine screening gain a competitive advantage by providing patients with more accurate and comfortable scans, generally with equivalent or lower radiation exposure than when synthetic 2D pictures are used. Strategically, investing in DBT promotes quality-based care initiatives, improves compliance with breast screening standards, and reinforces a facility's reputation for providing advanced, patient-centered diagnostics.

Based on End-User, this segment includes Hospitals and Specialty Clinics, Diagnostic Imaging Centers, Research & Academic Institute. The Hospitals and Specialty Clinics segment dominated the global market in 2024, while the Diagnostic Imaging Centers segment is projected to be the fastest–growing segment during the forecast period. Hospitals and specialty clinics are representing important end-user sectors in the tomosynthesis industry, with each playing a crucial role in its continued expansion. Hospitals dominate the market because of their extensive diagnostic infrastructure, ability to handle large patient volumes, and integration of modern imaging technologies into multidisciplinary treatment pathways. Their investment in DBT is consistent with larger institutional aims such as improving diagnostic accuracy, patient outcomes, and satisfying value-based care criteria. In parallel, specialized clinics, particularly imaging and women's health centers, emerging as significant providers, utilizing DBT to provide accessible, early detection services in outpatient settings. Their focused service delivery strategy and smaller operating costs allow for rapid adoption of new technologies, positioning them as significant drivers of market expansion and innovation.

Regional Analysis

Geographically, the Global Digital Breast Tomosynthesis (DBT) Market has been segmented into North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Major demand factors driving the North America market are the increasing prevalence of breast cancer and technological advancements and shift toward early and preventive diagnosis. The North American tomosynthesis market is expanding rapidly, driven by a number of major factors such as rising breast cancer rates, technological improvements, and increased need for more precise diagnostic techniques. For example, the prevalence of breast cancer in North America is rising. According to the American Cancer Society, approximately one out of every eight women in the United States may acquire breast cancer over their lifetime. This has resulted in increased adoption of advanced screening methods, such as tomosynthesis, which improves early detection rates. The increased awareness of breast cancer, combined with updated screening standards, is encouraging healthcare professionals to use digital breast tomosynthesis (DBT) as a tool to improve early diagnosis and eliminate false positives often associated with traditional mammography.

The European tomosynthesis market is expanding rapidly, driven by the rising frequency of breast cancer, advances in imaging technology, and a growing desire for more precise and efficient diagnostic techniques. As the prevalence of breast cancer in the region rises, the use of digital breast tomosynthesis (DBT) is gaining traction, particularly in nations with established national screening programs such as Germany, France and Sweden. For instance, according to the European Commission’s Cancer Screening Report (2022), about 80% of European women aged 50-69 are now covered by organized breast cancer screening programs, with many countries integrating 3D mammography or tomosynthesis into their screening protocols. The use of artificial intelligence (AI) into DBT systems improves diagnosis accuracy and operational efficiency, which accelerates adoption. Government initiatives, expanded reimbursement policies, and increased public knowledge of the benefits of early cancer screening all help to drive market growth.

The Asia-Pacific tomosynthesis market is expanding rapidly, fueled by the region's rising breast cancer incidence and increased healthcare investments. With predictions of considerable growth in the next years, particularly in China, India, Japan, and South Korea. As breast cancer diagnoses rise—China alone witnessed over 300,000 new cases in 2020, according to the World Health Organization—demand for improved screening technologies such as digital breast tomosynthesis (DBT) grows. Moreover, the American Cancer Society's article released in January 2024 predicts that breast cancer fatalities in Southeast Asia will rise to 61.7% by 2040. This is anticipated to accelerate the adoption of digital breast tomosynthesis in this region. The incorporation of artificial intelligence (AI) into DBT systems improves diagnosis accuracy and efficiency, making it a top choice for early detection, particularly in nations with strong healthcare systems such as Japan and South Korea.

The tomosynthesis market in South America is gradually expanding, driven by rising breast cancer awareness, advances in imaging technology, and increased healthcare access throughout the area. With continuous rise projected as more nations implement digital breast tomosynthesis (DBT) for early cancer detection. Breast cancer is still the top cause of cancer in women in South America, with a projected 160,000 new cases in 2020, according to the International Agency for Research on Cancer (IARC). This increased incidence has prompted healthcare professionals in Brazil, Argentina, and Chile to invest in more accurate diagnostic technologies, such as DBT, which outperforms standard mammography, particularly in women with dense breast tissue.

The tomosynthesis market in the Middle East and Africa (MEA) is emerging as a key growth sector, owing to increased breast cancer awareness, improvements in healthcare infrastructure, and advances in diagnostic technologies. With tremendous increase expected in the next years. Breast cancer is the most frequent cancer among women in the region, with the World Health Organization (WHO) reporting over 100,000 new cases per year in the MEA region. Countries such as the United Arab Emirates, Saudi Arabia, and South Africa are rapidly using digital breast tomosynthesis (DBT) to combat the rising breast cancer incidence and improve early detection rates.

Key Findings of the Study

• The Global Digital Breast Tomosynthesis (DBT) Market is expected to reach USD 13.18 billion by 2035, at a CAGR of 11.68% during the forecast period.


• The North America region accounted for the fastest-growing global market.


• Based on the Product, the 2D/3D Combo segment was attributed to holding the largest market in 2024.


• Hologic, Inc., GE HealthCare, FUJIFILM Holdings Corporation, Trivitron Healthcare Private Limited, Planmed Oy, Siemens Healthineers, PerkinElmer, Canon Medical Systems Corporation, Analogic Corporation, Shimadzu Corporation, NP JSC AMICO, VMI Médica, BEMEMS Co., Ltd., Sino Medical-Device Technology Co., Ltd., Shenzhen Landwind Industry Co., Payamed Electronic Industries Co., Medical Technologies Ltd. (MTL), Metaltronica S.p.A., Lotus Healthcare, Koninklijke Philips N.V., Allengers Medical Systems Ltd., IMS Giotto S.p.A., Shenzhen Angell Technology Co., Ltd., Konica Minolta, Inc., Electron Co. are some of the players in the market.